Vitamin c boost: could high doses help fight bone marrow cancer?

NCT ID NCT07283900

Recruiting now Disease control Sponsor: Prajwal Dhakal Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether adding high-dose vitamin C to a standard chemotherapy drug (azacitidine) can improve outcomes for adults with myelodysplastic syndrome (MDS), a bone marrow disorder. About 38 people with higher-risk MDS who haven't had much prior treatment will receive the combination intravenously. The goal is to see if the combo is safe and leads to remission or better survival.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: high-dose vitamin C (ascorbate) and azacitidine (Vidaza)
What this could lead to: If it works, this could point toward a more effective treatment for myelodysplastic syndrome, potentially improving remission rates and survival.
What could go wrong: This is a small, early-phase trial with only 38 participants, so results may not apply to everyone. High-dose vitamin C can cause side effects like kidney stones or infusion reactions.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MYELODYSPLASTIC SYNDROMES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

myelodysplastic syndrome Myelodysplastic Syndromes

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MYELODYSPLASTIC SYNDROMES

Contacts and locations

Locations

University of Iowa
RECRUITING

Iowa City, Iowa, 52242, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.